Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
Restores Gene Function to Double Survival and Incr...wed medical journal The Lancet Oncology confirms vidaza
extends survival for patients with higher-risk MDS...
"The data from this large international study of vidaza
is important news for the patients we represent, v...
Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
...sponse rates, for Dacogen(R) versus Vidaza(R).
"Findings from this trial could help clarify the fundamental differences between Dacogen and vidaza
and ultimately help clinicians with treatment selection," said Dr. Anastasios Raptis, co-director, Myelodysplastic Syndrome Program, attending, Stem C...
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
...nd chief executive officer of Pharmion.
and MGCD0103 showcase Pharmion's highly complement...planned three-arm randomized study of MGCD0103 and vidaza
in AML and MDS
The study entitled, "P...ory AML, or untreated patients with
AML were given vidaza
at its approved dose/schedule (75 mg/m2 SC daily f...
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
... release contains forward-looking statements, including summary
statements relating to the interim or preliminary results of clinical
trials involving vidaza
and MGCD0103. Such statements are based on current
expectations and involve a number of known and unknown risks and
uncertainties that could cause the...
Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
...ocus on the
detailed presentation of data from the vidaza
overall survival study, which
demonstrate an unpre... the meeting include alternate dosing schedules of vidaza
the use of vidaza
as a maintenance therapy for patients with higher-...
Vidaza in Medical Technology
Clinical Data Reported on Vidaza in Hematologic Malignancies and
Advanced Solid Tumors
HDAC Inhibitor MGCD0103 Demonstrates substantial Response Rate
in Two Clinical Trials
Clinical Data Presented on Pilot Pharmacokinetic Study of Oral
Exelixis Reports Comprehensive XL880 Phase I Data At ASCO
Exelixis Reports Integrated Data From Phase II Clinical Trials
of XL999 a...
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
...ata from largest Phase 3 study conducted in MDS - vidaza
therapy confers highly significant 9.4 month media...ens
- Two year overall survival rate of 50.8% for vidaza
compared to 26.2% for conven... to the EMEA, given the
highly compelling data for vidaza
in the treatment of MDS," said Patrick J.
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Patients will receive 75 mg/m2 of vidaza
either intravenously or
subcutaneously in combinat...are delighted to be participating in this trial of vidaza
MGCD0103," commented Dr. Anas Younes, Professo...of
In May 2004, vidaza
became the first drug approved by the FDA for the
MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
...ered subcutaneous every four weeks for six cycles: vidaza
mg/m2/day x 5 days, two days off therapy...l days at same dose
as the first five days; N=50); vidaza
5-2-5 (50 mg/m2/day x 5 days,
followed by 2 days o...ys at the same dose as
the first five days; N=51); vidaza
5 (75 mg/m2/day x 5 days; N=50). The
majority of p...
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
... Two year survival rate of 50.8 percent for vidaza
versus 26.2 for conventional...9.4 months median survival benefit for patients on vidaza
compared to conventional car...syndromes (MDS). In the primary endpoint analysis, vidaza
associated with a median survival of...
Pharmion to Present Clinical Data on Commercial and Pipeline
Products at 2007 American Society of Clinical Oncology (ASCO)
...six of our products will be presented or
published, including Phase III data for Satraplatin and
Thalidomide, encouraging Phase II data for Amrubicin, vidaza
MGCD0103, and human bioavailability data for oral azacitidine.
These data demonstrate the strength of the Pharmion business model;
we are focused ...
Vidaza in Biological News
The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data
Crosswicks, NJ (August 22, 2008) The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA
(azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the o...
FDA approves Vidaza label expansion
Washington D.C. (August 21, 2008) The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the U.S. Food & Drug Administration (FDA) has expanded the label for VIDAZA
(azacitidine) to include data from the AZA-001 trial, which found that Vidaza
is the only...
The MDS foundation supports vidaza's recommendation for European approval
...ucts for Human Use (CHMP) recommending approval of vidaza
(azacitidine) for specific types of MDS patients, ...upon data from the AZA-001 trial, which found that vidaza
nearly doubled the two-year survival rate for high... of life."
The AZA-001 trial also showed that, vidaza
delays the progression of MDS to acute myeloid leu...
Vidaza receives positve opinion from European CHMP
... European Committee for Medicinal Products for Human Use (CHMP) has awarded vidaza
(azacitidine) a positive opinion for the treatment of myelodysplastic syndr...tients' lives, but also improves their quality of life. We are hopeful that vidaza
will receive marketing approval shortly and quickly be available for patien...
Vidaza in Biological Technology